Business Wire10.25.21
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, has been issued a patent from the United States Patent and Trademark Office (No. 11,065,645) entitled “Method and system for generating mechanical pulses.”
The patent is directed to a general system comprising a shock wave generator connected to a mechanical waveguide, for the treatment of lesions in blood vessels. It protects the novel Soundbite system architecture, which is used in all products of the company's burgeoning portfolio.
The patent is expected to expire in December 2036 and will continue to provide key intellectual property protection for the company's technology platform.
This is the fourth U.S. patent to be issued around the approved Soundbite technology. Soundbite continues to enhance its patent portfolio with additional patent applications that will broaden and strengthen its patent protection in key markets throughout the world.
“The strength of our patent portfolio is a testament to our talented engineering team. The pursuit of excellence in serving our patients begins with medical devices that are unique, differentiated and of the highest quality. Protecting that work and preserving value will establish Soundbite as a leader in its field,” said Lori Chmura, president and CEO of Soundbite.
The SoundBite Crossing System—Peripheral (SCS-P)—consists of the reusable SoundBite Console, a single-use sterile SoundBite Active Wire, and their respective accessories. SCS-P leverages Soundbite’s proprietary method to produce and safely deliver shock waves via guidewire platforms to selectively “micro- jackhammer” through calcified lesions.
High calcium burden is present in up to 50 percent of peripheral artery disease patients with severe claudication and in >65 percent of patients with critical limb ischemia (CLI), especially in difficult to treat below-the-knee disease. Chronic total occlusions are encountered in up to 50 percent of PAD and CLI patients. CLI is associated with a high risk of lower limb amputation estimated in 10 percent to 40 percent of patients at six months, especially in non-treatable patients.
Soundbite is a privately-held medical device company uniquely dedicated to developing meaningful solutions for the interventional treatment of calcific peripheral and coronary arterial diseases. Soundbite has developed and deployed a proprietary method to produce and safely deliver shock waves to calcified lesions using an array of devices to improve and transform the standard of care for treatment of patients suffering from calcified and occlusive cardiovascular disease.
The patent is directed to a general system comprising a shock wave generator connected to a mechanical waveguide, for the treatment of lesions in blood vessels. It protects the novel Soundbite system architecture, which is used in all products of the company's burgeoning portfolio.
The patent is expected to expire in December 2036 and will continue to provide key intellectual property protection for the company's technology platform.
This is the fourth U.S. patent to be issued around the approved Soundbite technology. Soundbite continues to enhance its patent portfolio with additional patent applications that will broaden and strengthen its patent protection in key markets throughout the world.
“The strength of our patent portfolio is a testament to our talented engineering team. The pursuit of excellence in serving our patients begins with medical devices that are unique, differentiated and of the highest quality. Protecting that work and preserving value will establish Soundbite as a leader in its field,” said Lori Chmura, president and CEO of Soundbite.
The SoundBite Crossing System—Peripheral (SCS-P)—consists of the reusable SoundBite Console, a single-use sterile SoundBite Active Wire, and their respective accessories. SCS-P leverages Soundbite’s proprietary method to produce and safely deliver shock waves via guidewire platforms to selectively “micro- jackhammer” through calcified lesions.
High calcium burden is present in up to 50 percent of peripheral artery disease patients with severe claudication and in >65 percent of patients with critical limb ischemia (CLI), especially in difficult to treat below-the-knee disease. Chronic total occlusions are encountered in up to 50 percent of PAD and CLI patients. CLI is associated with a high risk of lower limb amputation estimated in 10 percent to 40 percent of patients at six months, especially in non-treatable patients.
Soundbite is a privately-held medical device company uniquely dedicated to developing meaningful solutions for the interventional treatment of calcific peripheral and coronary arterial diseases. Soundbite has developed and deployed a proprietary method to produce and safely deliver shock waves to calcified lesions using an array of devices to improve and transform the standard of care for treatment of patients suffering from calcified and occlusive cardiovascular disease.